ASST Fatebenefratelli Sacco
Quick facts
Marketed products
Phase 3 pipeline
- continue the PI/r-containing HAART. · Infectious disease
Ritonavir is a protease inhibitor used to treat HIV-1 infection by preventing the replication of the virus. - RPV + DRV/r · Infectious Disease / Virology
RPV (rilpivirine) and DRV/r (darunavir/ritonavir) are antiretroviral agents that inhibit HIV reverse transcriptase and protease, respectively, blocking viral replication. - Slit One
Slit One is a drug that works by inhibiting the action of a specific protein. - Slit One ragweed · Immunology / Allergy
Slit One ragweed is a sublingual immunotherapy that desensitizes the immune system to ragweed allergen through gradual exposure under the tongue.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about ASST Fatebenefratelli Sacco
What are ASST Fatebenefratelli Sacco's marketed drugs?
Top marketed products include Hyoscine N-Butil Bromide, Ibuprofen 400 mg, low-volume PEG -ascorbic acid.
What is ASST Fatebenefratelli Sacco's pipeline?
ASST Fatebenefratelli Sacco has 4 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include continue the PI/r-containing HAART., RPV + DRV/r, Slit One, Slit One ragweed.